Investigating the effects of stopping beta-blockers in older adults with heart failure.
Official title: DEPRESCRIBE-HFPEF
Funded at Weill Medical Coll of Cornell Univ · NIH-11027886 · Data updated 2026-11-12
This study is looking at older adults with heart failure who are taking beta-blockers to see if stopping this medication can improve their health and quality of life, helping doctors make better treatment decisions for their patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $698,754 |
| NIH project number | 1R01AG091005-01 |
| Project ID | NIH-11027886 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults diagnosed with heart failure with preserved ejection fraction who are currently taking beta-blockers.
✕Less likely to help
Patients with heart failure with reduced ejection fraction or those not currently prescribed beta-blockers may not benefit from this research.
What this research studies
This research focuses on older adults suffering from heart failure with preserved ejection fraction (HFpEF), a condition that affects over 3 million people in the U.S. The study aims to evaluate the impact of deprescribing beta-blockers, a common medication that may not provide benefits and could potentially worsen health-related quality of life in these patients. By analyzing the safety and efficacy of stopping beta-blockers, the research seeks to provide clearer guidelines for treatment and improve patient outcomes. Participants will be monitored for changes in their health status and quality of life after discontinuing the medication.
Why it matters
Potential benefit: If successful, this research could lead to improved health outcomes and quality of life for older adults with HFpEF by providing evidence for safer medication practices.
How similar studies have gone: While there is limited evidence regarding the deprescribing of beta-blockers in HFpEF, this research addresses a critical gap and aims to provide new insights into treatment practices.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Goyal, Parag — Weill Medical Coll of Cornell Univ
- Study coordinator: Goyal, Parag
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.